Cargando…

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer

BACKGROUND: Androgen deprivation therapy (ADT) is a standard treatment for patients with aggressive prostate cancer. Although ADT improves survival, it increases the risk of diabetes. Emerging evidence suggests that ADT increases adverse cardiovascular events as early as 3 months after initiation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Paul L., Jarolim, Petr, Basaria, Shehzad, Zuflacht, Jonah P., Milian, Jessica, Kadivar, Samoneh, Graham, Powell L., Hyatt, Andrew, Kantoff, Philip W., Beckman, Joshua A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579953/
https://www.ncbi.nlm.nih.gov/pubmed/25896892
http://dx.doi.org/10.1161/JAHA.115.001914
_version_ 1782391347808829440
author Nguyen, Paul L.
Jarolim, Petr
Basaria, Shehzad
Zuflacht, Jonah P.
Milian, Jessica
Kadivar, Samoneh
Graham, Powell L.
Hyatt, Andrew
Kantoff, Philip W.
Beckman, Joshua A.
author_facet Nguyen, Paul L.
Jarolim, Petr
Basaria, Shehzad
Zuflacht, Jonah P.
Milian, Jessica
Kadivar, Samoneh
Graham, Powell L.
Hyatt, Andrew
Kantoff, Philip W.
Beckman, Joshua A.
author_sort Nguyen, Paul L.
collection PubMed
description BACKGROUND: Androgen deprivation therapy (ADT) is a standard treatment for patients with aggressive prostate cancer. Although ADT improves survival, it increases the risk of diabetes. Emerging evidence suggests that ADT increases adverse cardiovascular events as early as 3 months after initiation in patients with cardiovascular disease, but the mechanism is unknown. We hypothesized that ADT may impair endothelium‐dependent vasodilation due to increases in lipids and insulin resistance and may provide a link for heightened cardiovascular risk in this population. METHODS AND RESULTS: We prospectively evaluated conduit artery endothelium‐dependent and ‐independent vasodilation, lipids, and insulin resistance in 16 consecutively treated men (mean age 66±7 years; 25% with diabetes) with prostate cancer before and after 3 months of ADT. High‐resolution B‐mode ultrasound was used to assess flow‐mediated (endothelium‐dependent) and nitroglycerine‐mediated (endothelium‐independent) brachial artery vasodilation. ADT significantly increased insulin resistance, total cholesterol, HDL, and LDL. Endothelium‐dependent vasodilation was greater at 3 months than at baseline (10.8% [interquartile range: 7.7% to 14.6%] versus 8.9% [interquartile range: 4.0% to 12.6%], respectively; P=0.046, allometric P=0.037). Nitroglycerine‐mediated vasodilation did not change from baseline (P>0.2). The subset of participants on ADT for 6 months returned for reevaluation at 1 year. In this group, endothelium‐dependent vasodilation increased from baseline to 3 months and returned to baseline 6 months after ADT withdrawal (9.4% [interquartile range: 6.9% to 10.9%], 11.6% [interquartile range: 7.9% to 15.2%], and 9.0% [interquartile range: 5.1% to 12.5%], respectively; P=0.05). CONCLUSIONS: In contrast to our expectation, ADT improved endothelium‐dependent vasodilation and its cessation returned endothelium‐dependent vasodilation to baseline. Determining the mechanism of this change requires further investigation.
format Online
Article
Text
id pubmed-4579953
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-45799532015-09-29 Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer Nguyen, Paul L. Jarolim, Petr Basaria, Shehzad Zuflacht, Jonah P. Milian, Jessica Kadivar, Samoneh Graham, Powell L. Hyatt, Andrew Kantoff, Philip W. Beckman, Joshua A. J Am Heart Assoc Original Research BACKGROUND: Androgen deprivation therapy (ADT) is a standard treatment for patients with aggressive prostate cancer. Although ADT improves survival, it increases the risk of diabetes. Emerging evidence suggests that ADT increases adverse cardiovascular events as early as 3 months after initiation in patients with cardiovascular disease, but the mechanism is unknown. We hypothesized that ADT may impair endothelium‐dependent vasodilation due to increases in lipids and insulin resistance and may provide a link for heightened cardiovascular risk in this population. METHODS AND RESULTS: We prospectively evaluated conduit artery endothelium‐dependent and ‐independent vasodilation, lipids, and insulin resistance in 16 consecutively treated men (mean age 66±7 years; 25% with diabetes) with prostate cancer before and after 3 months of ADT. High‐resolution B‐mode ultrasound was used to assess flow‐mediated (endothelium‐dependent) and nitroglycerine‐mediated (endothelium‐independent) brachial artery vasodilation. ADT significantly increased insulin resistance, total cholesterol, HDL, and LDL. Endothelium‐dependent vasodilation was greater at 3 months than at baseline (10.8% [interquartile range: 7.7% to 14.6%] versus 8.9% [interquartile range: 4.0% to 12.6%], respectively; P=0.046, allometric P=0.037). Nitroglycerine‐mediated vasodilation did not change from baseline (P>0.2). The subset of participants on ADT for 6 months returned for reevaluation at 1 year. In this group, endothelium‐dependent vasodilation increased from baseline to 3 months and returned to baseline 6 months after ADT withdrawal (9.4% [interquartile range: 6.9% to 10.9%], 11.6% [interquartile range: 7.9% to 15.2%], and 9.0% [interquartile range: 5.1% to 12.5%], respectively; P=0.05). CONCLUSIONS: In contrast to our expectation, ADT improved endothelium‐dependent vasodilation and its cessation returned endothelium‐dependent vasodilation to baseline. Determining the mechanism of this change requires further investigation. Blackwell Publishing Ltd 2015-04-20 /pmc/articles/PMC4579953/ /pubmed/25896892 http://dx.doi.org/10.1161/JAHA.115.001914 Text en © 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Nguyen, Paul L.
Jarolim, Petr
Basaria, Shehzad
Zuflacht, Jonah P.
Milian, Jessica
Kadivar, Samoneh
Graham, Powell L.
Hyatt, Andrew
Kantoff, Philip W.
Beckman, Joshua A.
Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
title Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
title_full Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
title_fullStr Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
title_full_unstemmed Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
title_short Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
title_sort androgen deprivation therapy reversibly increases endothelium‐dependent vasodilation in men with prostate cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579953/
https://www.ncbi.nlm.nih.gov/pubmed/25896892
http://dx.doi.org/10.1161/JAHA.115.001914
work_keys_str_mv AT nguyenpaull androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT jarolimpetr androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT basariashehzad androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT zuflachtjonahp androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT milianjessica androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT kadivarsamoneh androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT grahampowelll androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT hyattandrew androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT kantoffphilipw androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer
AT beckmanjoshuaa androgendeprivationtherapyreversiblyincreasesendotheliumdependentvasodilationinmenwithprostatecancer